Lessons from other fields of medicine, Part 1: Breast cancer

Ashikaga, 2010, Morbidity results from the NSABP B-32 trial comparing sentinel lymph node dissection vs axillary dissection, J Surg Oncol, 102, 111, 10.1002/jso.21535 Beatson, 1896, On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases, Trans Med Chir Soc Edinb, 15, 153 Bertucci, 2013, Comparison of the prognostic value of genomic grade index, Ki67 expression, and mitotic activity index in early node-positive breast cancer patients, Ann Oncol, 24, 625, 10.1093/annonc/mds510 Breasted, 1930 Buyse, 2006, Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer, J Natl Cancer Inst, 98, 1183, 10.1093/jnci/djj329 Cancer Genome Atlas Network, 2012, Comprehensive molecular portraits of human breast tumours, Nature, 490, 61, 10.1038/nature11412 Cardoso, 2016, 70-gene signature as an aid to treatment decisions in early-stage breast cancer, N Engl J Med, 375, 717, 10.1056/NEJMoa1602253 Cardoso, 2020, MINDACT: long-term results of the large prospective trial testing the 70-gene signature MammaPrint as guidance for adjuvant chemotherapy in breast cancer patients, J Clin Oncol, 38, 506, 10.1200/JCO.2020.38.15_suppl.506 Caudle, 2016, Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection, J Clin Oncol, 34, 1072, 10.1200/JCO.2015.64.0094 Chia, 2012, A 50-gene intrinsic subtype classifier for prognosis and prediction of benefit from adjuvant tamoxifen, Clin Cancer Res, 18, 4465, 10.1158/1078-0432.CCR-12-0286 Coates, 2015, Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015, Ann Oncol, 26, 1533, 10.1093/annonc/mdv221 Cobain, 2015, Indications for prognostic gene expression profiling in early breast cancer, Curr Treat Options Oncol, 16, 23, 10.1007/s11864-015-0340-x Cotlar, 2003, History of surgery for breast cancer: radical to the sublime, Curr Surg, 60, 329, 10.1016/S0149-7944(02)00777-8 Crile, 1965, Treatment of breast cancer by local excision, Am J Surg, 109, 400, 10.1016/S0002-9610(65)80161-1 Davies, 2013, Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial, Lancet, 381, 805, 10.1016/S0140-6736(12)61963-1 De Gouvea, 2017, Breast cancer genetics, 73 Denkert, 2012, Decentral gene expression analysis for ER+/HER2- breast cancer: results of a proficiency testing program for the EndoPredict assay, Virchows Arch, 460, 251, 10.1007/s00428-012-1204-4 Desmedt, 2007, Strong time depen- dence of the 76-gene prognostic signature for node- negative breast cancer patients in the TRANSBIG multicenter independent validation series, Clin Cancer Res, 13, 3207, 10.1158/1078-0432.CCR-06-2765 Donker, 2014, Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial, Lancet Oncol, 15, 1303, 10.1016/S1470-2045(14)70460-7 Donker, 2015, Marking axillary lymph nodes with radioactive iodine seeds for axillary staging after neoadjuvant systemic treatment in breast cancer patients, Ann Surg, 261, 378, 10.1097/SLA.0000000000000558 Dowsett, 2013, Com- parison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy, J Clin Oncol, 31, 2783, 10.1200/JCO.2012.46.1558 Dubsky, 2013, The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2- breast cancer patients, Br J Cancer, 2013, 2959, 10.1038/bjc.2013.671 Duffy, 2017, Clinical use of biomarkers in breast cancer: updated guidelines from the European Group on Tumor Markers (EGTM), Eur J Cancer, 75, 284, 10.1016/j.ejca.2017.01.017 Duffy, 2018, Mutant p53 in breast cancer: potential as a therapeutic target and biomarker, Breast Cancer Res Treat, 170, 213, 10.1007/s10549-018-4753-7 2015, Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials, Lancet, 386, 1341, 10.1016/S0140-6736(15)61074-1 Ellis, 2018 Esserman, 2017, Use of molecular tools to identify patients with indolent breast cancers with ultralow risk over 2 decades, JAMA Oncol, 3, 1503, 10.1001/jamaoncol.2017.1261 Filipits, 2014, The PAM50 risk-of-recurrence score predicts risk for late distant recurrence after endocrine therapy in postmenopausal women with endocrine-responsive early breast cancer, Clin Cancer Res, 20, 1298, 10.1158/1078-0432.CCR-13-1845 Fisher, 1989, Eight-year results of a randomized clinical trial comparing total mastectomy and lumpectomy with or without irradiation in the treatment of breast cancer, N Engl J Med, 320, 822, 10.1056/NEJM198903303201302 Fisher, 1993, Lumpectomy compared with lumpectomy with radiation therapy for the treatment of intraductal breast cancer, N Engl J Med, 328, 1581, 10.1056/NEJM199306033282201 Fisher, 1996, J Clin Oncol, 14, 1982, 10.1200/JCO.1996.14.7.1982 Fisher, 2002, Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation, N Engl J Med, 347, 567, 10.1056/NEJMoa020128 Fisher, 2002, Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer, N Engl J Med, 347, 1233, 10.1056/NEJMoa022152 Fisher, 2002, Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18, Cancer, 95, 681, 10.1002/cncr.10741 Fisher, 2004, Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials, Lancet, 364, 858, 10.1016/S0140-6736(04)16981-X Fisher, 2005, Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study, J Natl Cancer Inst, 97, 1652, 10.1093/jnci/dji372 Foster, 2003, Breast cancer detection and treatment: a personal and historical perspective, Arch Surg, 138, 397, 10.1001/archsurg.138.4.397 Garrison, 1914 Gasco, 2002, The p53 pathway in breast cancer, Breast Cancer Res, 4, 70, 10.1186/bcr426 Giuliano, 2017, Ann Surg, 264, 413, 10.1097/SLA.0000000000001863 Goldhirsch, 2013, Personalizing the treatment of women with early breast cancer: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer, Ann Oncol, 24, 2206, 10.1093/annonc/mdt303 Harbeck, 2013, Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients, Eur J Cancer, 49, 1825, 10.1016/j.ejca.2013.01.007 Hayes, 1988, CA 15-3 and CEA spikes during chemotherapy for metastatic breast cancer, Proc Am Clin Oncol, 7, 38 Hudack, 1933, The lymphatic participation in human cutaneous phenomena: a study of the minute lymphatics of the living skin, J Exp Med, 57, 751, 10.1084/jem.57.5.751 Hudziak, 1989, p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor, Mol Cell Biol, 9, 1165 Hughes, 2013, Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343, J Clin Oncol, 31, 2382, 10.1200/JCO.2012.45.2615 International Breast Cancer Study Group, 2004, Toremifene and tamoxifen are equally effective for early-stage breast cancer: first results of International Breast Cancer Study Group Trials 12-93 and 14-93, Ann Oncol, 15, 1749, 10.1093/annonc/mdh463 Janicke, 2001, Randomized adjuvant chemotherapy trial in high-risk node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1, J Natl Cancer Inst, 93, 913, 10.1093/jnci/93.12.913 Jensen, 2010, Estrogen action: a historic perspective on the implications of considering alternative approaches, Physio Behav, 99, 151, 10.1016/j.physbeh.2009.08.013 Jerevall, 2011, Prognostic utility of HOXB13:IL17BR and molecular grade index in early- stage breast cancer patients from the Stockholm trial, Br J Cancer, 104, 1762, 10.1038/bjc.2011.145 Kalinsky, 2021, Am Ass Cancer Res, 81 Krag, 2010, Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial, Lancet Oncol, 11, 927, 10.1016/S1470-2045(10)70207-2 Lewis, 2010, Excellent outcomes with adjuvant toremifene or tamoxifen in early stage breast cancer, Cancer, 116, 2307, 10.1002/cncr.24940 Liedtke, 2009, Genomic grade index is associated with response to chemotherapy in patients with breast cancer, J Clin Oncol, 27, 3185, 10.1200/JCO.2008.18.5934 Litton, 2019, Molecular testing in breast cancer, Am Soc Clin Oncol Educ Book, 39, e1, 10.1200/EDBK_237715 Loi, 2007, Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade, J Clin Oncol, 25, 1239, 10.1200/JCO.2006.07.1522 Longacre, 2006, Interobserver agreement and reproducibility in classification of invasive breast carcinoma: an NCI breast cancer family registry study, Mod Pathol, 19, 195, 10.1038/modpathol.3800496 Look, 2002, Pooled analysis of prognostic impact of tumor biological factors uPA and PAI-1 in 8377 breast cancer patients, J Natl Cancer Inst, 94, 116, 10.1093/jnci/94.2.116 Lukong, 2017, Understanding breast cancer—the long and winding road, BBA Clin, 7, 64, 10.1016/j.bbacli.2017.01.001 Magnani, 2017, Fundamental pathways in breast cancer: estrogen biology, 19 Mamounas, 2019, J Clin Oncol, 37, 10.1200/JCO.2019.37.15_suppl.TPS600 Marinho, 2020, The first mastectomy: truth or legend?, Mastology, 30, 10.29289/25945394202020200063 Martin, 2014, Clinical validation of the EndoPredict test in node-positive, chemotherapy- treated ER+/HER2− breast cancer patients: results from the GEICAM 9906 trial, Breast Cancer Res, 16, R38, 10.1186/bcr3642 Merrill, 2017, Breast surgery, 99 Metzger-Filho, 2013, Genomic grade index (GGI): feasibility in routine practice and impact on treatment decisions in early breast cancer, PLoS One, 8, 10.1371/journal.pone.0066848 Miki, 1994, A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1, Science, 266, 66, 10.1126/science.7545954 Muller, 1988, Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene, Cell, 54, 105, 10.1016/0092-8674(88)90184-5 Muller, 2012, Comparison of the RNA-based EndoPredict multigene test between core biopsies and corresponding surgical breast cancer sections, J Clin Pathol, 65, 660, 10.1136/jclinpath-2012-200716 Nieweg, 2015, The history of sentinel lymph node biopsy, Cancer J, 21, 3, 10.1097/PPO.0000000000000091 Paik, 2006, Evolving role of pathology in modern oncology, 17 Paik, 2004, A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer, N Engl J Med, 351, 2817, 10.1056/NEJMoa041588 Paik, 2006, Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor positive breast cancer, J Clin Oncol, 24, 3726, 10.1200/JCO.2005.04.7985 Papavramidou, 2010, Ancient Greek and Greco-Roman methods in modern surgical treatment of cancer, Ann Surg Oncol, 17, 665, 10.1245/s10434-009-0886-6 Parker, 2009, Supervised risk predictor of breast cancer based on intrinsic subtypes, J Clin Oncol, 27, 1160, 10.1200/JCO.2008.18.1370 Perez, 2014, Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831, J Clin Oncol, 32, 3744, 10.1200/JCO.2014.55.5730 Perou, 2000, Molecular portraits of human breast tumors, Nature, 406, 747, 10.1038/35021093 Piccart, 2021, 70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age, Lancet Oncol, 22, 476, 10.1016/S1470-2045(21)00007-3 Piccart-Gebhart, 2005, Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer, N Engl J Med, 353, 1659, 10.1056/NEJMoa052306 Prat, 2015, Clinical implications of the intrinsic molecular subtypes of breast cancer, Breast, 24, S26, 10.1016/j.breast.2015.07.008 Pruneri, 2017, Prognostic and predictive role of genetic signatures, 121 Pusztai, 2006, Molecular markers for treatment decision, 81 Rakha, 2008, Invasive lobular carcinoma of the breast: response to hormonal therapy and outcomes, Eur J Cancer, 44, 73, 10.1016/j.ejca.2007.10.009 Rakha, 2010, Breast cancer prognostic classification in the molecular era: the role of histological grade, Breast Cancer Res, 12, 207, 10.1186/bcr2607 Robson, 2017, Olaparib for metastatic breast cancer in patients with a germline BRCA mutation, N Engl J Med, 377, 523, 10.1056/NEJMoa1706450 Rosselli Del Turco, 1994, Intensive diagnostic follow up after treatment of primary breast cancer. A randomized trial. National Research Council Project on Breast Cancer follow-up, JAMA, 271, 1593, 10.1001/jama.1994.03510440053032 Slamon, 1987, Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene, Science, 235, 177, 10.1126/science.3798106 Slamon, 2001, Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2, N Engl J Med, 344, 783, 10.1056/NEJM200103153441101 Soutiriou, 2006, Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis, J Natl Cancer Inst, 98, 262, 10.1093/jnci/djj052 Sparano, 2018, Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer, N Engl J Med, 379, 111, 10.1056/NEJMoa1804710 Sparano, 2020, Clinical outcomes in early breast cancer with a high 21-gene recurrence score of 26 to 100 assigned to adjuvant chemotherapy plus endocrine therapy: a secondary analysis of the TAILORx randomized clinical trial, JAMA Oncol, 6, 367, 10.1001/jamaoncol.2019.4794 Swain, 2013, Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study, Lancet Oncol, 14, 461, 10.1016/S1470-2045(13)70130-X Sweep, 1998, External quality assessment of trans-European multicenter antigen determination (enzyme-linked immunosorbent assay) of urokinase plasminogen activator (uPA) and its type-1 inhibitor (PAI-1) in human breast cancer extracts, Br J Cancer, 78, 1434, 10.1038/bjc.1998.704 The Cancer Genome Atlas (TCGA), 2021 The GIVIO Investigators, 1994, Impact of follow up testing on survival and health related quality of life in breast cancer patients, JAMA, 271, 1587, 10.1001/jama.1994.03510440047031 Tutt, 2021, Adjuvant Olaparib for patients with BRCA1- or BRCA 2-mutated breast cancer, N Engl J Med, 384, 2394, 10.1056/NEJMoa2105215 van de Vijver, 2002, A gene-expression signature as a predictor of survival in breast cancer, N Engl J Med, 347, 1999, 10.1056/NEJMoa021967 van’t Veer, 2002, Gene expression profiling predicts clinical outcome of breast cancer, Nature, 415, 530, 10.1038/415530a Velpeau, 1854 Vogel, 2010, Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer, Cancer Prev Res, 3, 696, 10.1158/1940-6207.CAPR-10-0076 Wang, 2005, Gene-expression profiles to predict distant metastasis of lymph-node- negative primary breast cancer, Lancet, 365, 671, 10.1016/S0140-6736(05)17947-1 Wapnir, 2010, Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS, J Natl Cancer Inst, 103, 478, 10.1093/jnci/djr027 Wooster, 1995, Identification of the breast cancer susceptibility gene BRCA2, Nature, 378, 789, 10.1038/378789a0 Yamamoto, 1986, Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor, Nature, 319, 230, 10.1038/319230a0 Zhang, 2013, Breast cancer index identifies early-stage estrogen receptor- positive breast cancer patients at risk for early- and late-distant recurrence, Clin Cancer Res, 19, 4196, 10.1158/1078-0432.CCR-13-0804